The purpose of this study is to compare the usual treatment alone (radiation and chemotherapy) to adding maintenance nivolumab to the usual treatment for HPV positive oropharynx cancer.
Learn more about the ECOG-ACRIN EA3161 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
